首页膀胱肿瘤治疗及预后证据详情

[Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer]

原文: 2021 年 发布于 Front Endocrinol (Lausanne) 13 卷 第 11 期 283-291 浏览量:360次

作者: Pignot G. Sargos P.

作者单位: Department of Urooncology, Max Institute of Cancer Care, Max Smart Superspecialty Hospital Saket, New Delhi, India. University College of Medical Sciences, New Delhi, India. Department of Urology, PGIMER, Chandigarh, India. Department of Urooncology, Max Institute of Cancer Care, Max Smart Superspecialty Hospital Saket, New Delhi, India. Electronic address: gagangg@gmail.com.

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.1111/iju.14748

关键词: 非肌层浸润性膀胱癌 整块切除 经尿道膀胱肿瘤切除术 Meta分析

文献简介

Background Bladder cancer is one of the most common urological cancers all over the world, and NMIBC occupies almost 80% of recently diagnosed bladder cancer cases. Progress and recurrence of bladder cancer are the main problems during the disease. The level of TP53 mutation is obviously higher in the high stage than the lower. This meta-analysis is to evaluate the potential diagnosis feature of TP53 mutation by the expression of TP53 mutation of Ta stage vs high stage in bladder cancer. Methods A systematic search of databases was conducted, and some relevant articles were selected. Next, the meta-analysis was carried out according to the standard guidelines. Results There were seven researches in which 677 participants were selected at the basis of inclusion standard. TP53 mutation was associated highly with increased diagnosis of bladder cancer. We found that the high stage of bladder cancer has obviously higher level of TP53 mutation than the lower stage, and these patients of MIBC have higher expression of TP53 mutation compared with NMIBC. No significant publication bias has been observed in this meta-analysis. The expression of TP53 mutation might be a diagnose-related biomarker for lots of patients with bladder cancer. Conclusions The results of this meta-analysis provided further evidences that the expression of TP53 mutation was associated with the diagnosis efficiency of advanced bladder cancer. Higher expression of TP53 mutation was observed in the high stage of bladder cancer or the MIBC, and lower expression of TP53 mutation in the Ta stage of bladder cancer or the NMIBC. The expression level of TP53 mutation was probably a critical diagnosed biomarker in advanced bladder cancer.